Literature DB >> 466651

Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase.

A Abuchowski, T van Es, N C Palczuk, J R McCoy, F F Davis.   

Abstract

An L-glutaminase-L-asparaginase from Achromobacter has been rendered nonimmunogenic by the covalent attachment of polyethylene glycol (PEG) to nonessential amine groups of the enzyme. PEG-L-glutaminase-L-asparaginase exhibits a greatly enhanced half-life in the bloodstream compared to the unmodified enzyme in normal mice, and is effective in prolonging the survival of BDF1 mice inoculated ip with L5178Y cells. PEG-L-glutaminase-L-asparaginase appears rapidly in the blood following ip injection.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 466651

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  10 in total

1.  Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).

Authors:  Joanne Kurtzberg; Barbara Asselin; Mark Bernstein; George R Buchanan; Brad H Pollock; Bruce M Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2011-12       Impact factor: 1.289

2.  Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.

Authors:  L N Ramya; Krishna Kanth Pulicherla
Journal:  Pathol Oncol Res       Date:  2015-03-06       Impact factor: 3.201

Review 3.  Micellar nanocarriers: pharmaceutical perspectives.

Authors:  V P Torchilin
Journal:  Pharm Res       Date:  2006-11-16       Impact factor: 4.200

4.  Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus.

Authors:  Piyanuch Wonganan; Courtney C Clemens; Kathy Brasky; Lucio Pastore; Maria A Croyle
Journal:  Mol Pharm       Date:  2010-09-23       Impact factor: 4.939

5.  A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma.

Authors:  H B Muss; N Spell; D Scudiery; R L Capizzi; M R Cooper; J Cruz; D V Jackson; F Richards; C L Spurr; D R White
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

6.  Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.

Authors:  Wing H Tong; Inge M van der Sluis; Cathelijne J M Alleman; Raphaële R L van Litsenburg; Gertjan J L Kaspers; Rob Pieters; Carin A Uyl-de Groot
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

7.  A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function.

Authors:  S Rajagopalan; S L Gonias; S V Pizzo
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

Review 8.  Pharmaceutical and toxicological properties of engineered nanomaterials for drug delivery.

Authors:  Matthew Palombo; Manjeet Deshmukh; Daniel Myers; Jieming Gao; Zoltan Szekely; Patrick J Sinko
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-23       Impact factor: 13.820

9.  First-line treatment of acute lymphoblastic leukemia with pegasparaginase.

Authors:  Riccardo Masetti; Andrea Pession
Journal:  Biologics       Date:  2009-07-13

10.  Structural and kinetic characterization of guinea pig L-asparaginase type III.

Authors:  Amanda M Schalk; Arnon Lavie
Journal:  Biochemistry       Date:  2014-04-07       Impact factor: 3.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.